Header Logo

Connection

William Towner to Middle Aged

Back to Details
This is a "connection" page, showing publications William Towner has written about Middle Aged.
William Towner
Connection Strength
0.653
Middle Aged
  1. Effect of an Electronic Alert on Targeted HIV Testing Among High-Risk Populations. Perm J. 2018; 22:18-015.
    View in: PubMed
    Score: 0.066
  2. Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr. 2010 Apr; 53(5):614-8.
    View in: PubMed
    Score: 0.038
  3. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr. 2009 Aug 01; 51(4):367-73.
    View in: PubMed
    Score: 0.037
  4. Fracture Risk and Association With TDF Use Among People With HIV in Large Integrated Health Systems. J Acquir Immune Defic Syndr. 2023 12 01; 94(4):341-348.
    View in: PubMed
    Score: 0.025
  5. Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine. Vaccine. 2023 Jul 05; 41(30):4392-4401.
    View in: PubMed
    Score: 0.024
  6. Association Between 2-Dose vs 3-Dose Hepatitis B Vaccine and Acute Myocardial Infarction. JAMA. 2022 04 05; 327(13):1260-1268.
    View in: PubMed
    Score: 0.022
  7. Association of Number of Doses With Hepatitis B Vaccine Series Completion in US Adults. JAMA Netw Open. 2020 11 02; 3(11):e2027577.
    View in: PubMed
    Score: 0.020
  8. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016. JAMA Netw Open. 2020 06 01; 3(6):e207954.
    View in: PubMed
    Score: 0.019
  9. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 11 05; 383(19):1827-1837.
    View in: PubMed
    Score: 0.019
  10. Effect of Physical Activity Coaching on Acute Care and Survival Among Patients With Chronic Obstructive Pulmonary Disease: A Pragmatic Randomized Clinical Trial. JAMA Netw Open. 2019 08 02; 2(8):e199657.
    View in: PubMed
    Score: 0.018
  11. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. HIV Clin Trials. 2017 05; 18(3):118-125.
    View in: PubMed
    Score: 0.016
  12. Immunodeficiency, AIDS-related pneumonia, and risk of lung cancer among HIV-infected individuals. AIDS. 2017 04 24; 31(7):989-993.
    View in: PubMed
    Score: 0.016
  13. Examining HIV Viral Load in a Matched Cohort of HIV Positive Individuals With and Without Psoriasis. J Drugs Dermatol. 2017 Apr 01; 16(4):372-377.
    View in: PubMed
    Score: 0.016
  14. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defic Syndr. 2016 Apr 01; 71(4):413-9.
    View in: PubMed
    Score: 0.015
  15. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
    View in: PubMed
    Score: 0.014
  16. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015 Dec 31; 373(27):2599-607.
    View in: PubMed
    Score: 0.014
  17. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 01; 163(11):818-26.
    View in: PubMed
    Score: 0.014
  18. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 01; 163(11):809-17.
    View in: PubMed
    Score: 0.014
  19. The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDS. 2015 Nov; 29(11):582-90.
    View in: PubMed
    Score: 0.014
  20. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20; 373(8):705-13.
    View in: PubMed
    Score: 0.014
  21. Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status. AIDS Patient Care STDS. 2015 Jul; 29(7):370-8.
    View in: PubMed
    Score: 0.014
  22. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1167-73.
    View in: PubMed
    Score: 0.013
  23. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015 Apr 15; 60(8):1278-80.
    View in: PubMed
    Score: 0.013
  24. HIV infection and incidence of ischemic stroke. AIDS. 2014 Aug 24; 28(13):1911-9.
    View in: PubMed
    Score: 0.013
  25. Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr. 2014 Aug 15; 66(5):495-502.
    View in: PubMed
    Score: 0.013
  26. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014 Nov 01; 384(9954):1597-605.
    View in: PubMed
    Score: 0.013
  27. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014 Apr 24; 28(7):989-97.
    View in: PubMed
    Score: 0.013
  28. Hepatitis B testing and vaccination among adults with sexually transmitted infections in a large managed care organization. Clin Infect Dis. 2014 Jun; 58(12):1739-45.
    View in: PubMed
    Score: 0.013
  29. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):160-6.
    View in: PubMed
    Score: 0.013
  30. Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2012 Jun 01; 60(2):183-90.
    View in: PubMed
    Score: 0.011
  31. Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2012 Dec; 28(12):1630-6.
    View in: PubMed
    Score: 0.011
  32. Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia. AIDS Patient Care STDS. 2012 May; 26(5):253-5.
    View in: PubMed
    Score: 0.011
  33. HIV quality performance measures in a large integrated health care system. AIDS Patient Care STDS. 2011 Jan; 25(1):21-8.
    View in: PubMed
    Score: 0.010
  34. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010 Jul 17; 24(11):1765-70.
    View in: PubMed
    Score: 0.010
  35. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010 Jan; 53(1):62-9.
    View in: PubMed
    Score: 0.009
  36. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
    View in: PubMed
    Score: 0.009
  37. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study. HIV Clin Trials. 2008 May-Jun; 9(3):152-63.
    View in: PubMed
    Score: 0.008
  38. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):384-90.
    View in: PubMed
    Score: 0.008
  39. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 07; 370(9581):39-48.
    View in: PubMed
    Score: 0.008
  40. Risk of opportunistic infection in the HAART era among HIV-infected Latinos born in the United States compared to Latinos born in Mexico and Central America. AIDS Patient Care STDS. 2003 Jun; 17(6):267-75.
    View in: PubMed
    Score: 0.006

© 2024 Kaiser Permanente